The all-in-one platform to find and track your stocks and investments
Discover the features
Statistics
Market Cap
287 billion
PE Ratio
25.77 x
Beta (volatility)
0.17
Earnings Per Share
14.58
About
It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology,...
Price
Performance Comparison
| Roche Holding AG | |
|---|---|
| 1 year return |
+38 %
|
| 5 years return |
+38 %
|
Valuation
| Price to Book | Payout ratio | PEG Ratio |
|---|---|---|
| 7.97 | 83 % | 0.73 |
| Price to Sales | Price / FCF | E.V.R. |
|---|---|---|
| 4.6 | 3.85 |
Price–Earnings Ratio History
The Price–Earnings Ratio history is not available for this stock.
Dividend History
Uninter. Dividend
23 years
Frequency
1x / year
Dividends in 2024
March
Dividends in 2023
March
March
Dividends in 2023
March
Forward Annual Amount
$11.01
Ex-dividend
3/28/2025
Financials
Year-over-Year growth
Profitability
Health
News
European Commission approves Roche’s Lunsumio subcutaneous for relapsed or refractory follicular lymphoma
11/19/2025
RHHBY Reports Positive Phase III Data on Breast Cancer Drug
11/18/2025
Roche's $15 Billion Breast Cancer Pill Just Stunned the Market--But AstraZeneca Is Lurking
11/18/2025
Why Roche's Positive Test Results Sent Olema Pharma Skyrocketing 130%
11/18/2025
Idiopathic Pulmonary Fibrosis Research Report 2025-2035: Market Led by Roche, Pliant Therapeutics, Bristol-Myers Squibb, and Vicore as Next-Gen Antifibrotics and Targeted Therapies Drive Innovation
11/18/2025
Klarna, PDD, Xiaomi: Companies Overseas in Focus
11/18/2025
Freenome Announces Exclusive Agreement with Roche to Expand Technology Collaboration and Develop and Commercialize Cancer Screening Tests Outside the U.S.
11/18/2025
Human Papilloma Virus (HPV) Test and Pap Smear/Test Market Research and Forecast Report 2025-2030, Competitive Analysis of Market leaders - Hologic, BD, Roche, QIAGEN, and Danaher
11/18/2025
Roche Shares Rise After Breast-Cancer Pill Shows Positive Results in Trial
11/18/2025
Genentech’s Giredestrant Becomes the First Oral SERD to Show Superior Invasive Disease-Free Survival in Early Breast Cancer
11/18/2025
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s giredestrant becomes the first oral SERD to show superior invasive disease-free survival in early breast cancer
11/18/2025
FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings
11/17/2025
Create a portfolio & add this stock
Add this stock and others to your own virtual portfolio and get personalised information : total annual dividends & total value, sectors breakdown, etc.
Privacy Policy • Terms and Conditions
© Copyright 2020-2025 Epsylia OÜ - All rights reserved
Moning is a platform that does not manage any funds and is purely educational. We do not provide any investment advice.
The data presented comes from different providers and may contain errors. We encourage you to always verify information through other sources.
Any financial investment involves risks including partial or total loss of capital.
The data presented comes from different providers and may contain errors. We encourage you to always verify information through other sources.
Any financial investment involves risks including partial or total loss of capital.